Expression Level and Clinical Significance of LncRNA PVT1 in the Serum of Patients with LEASO

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2023 Sep 25

PMID 37744231

Authors

Xiaoxue Su

Xiaoqing Yuan

FengHui Li

Guinan Yang

Liunianbo Du

Fule Zhao

Rui Zhao

MingHui Ou

Affiliations

Soon will be listed here.

Abstract

Objective: Our study aims to investigate the long non-coding RNA plasmacytoma variant translocation 1 (lncRNA PVT1) in lower extremity arteriosclerosis obliterans (LEASO) patient serum and its clinical significance in LEASO.

Patients And Methods: From July 2021 to April 2022, 133 LEASO patients diagnosed at the Qingdao Municipal Hospital were included. Among them, 44 complicated with coronary artery disease (CAD) were classified as the LEASO with CAD group. The remaining 89 were marked as the LEASO group, which was classified into single ( = 48) and double ( = 41) lower limb groups, with the former being subclassified into the left ( = 28) and right ( = 20) lower limb groups based on the affected sites. Fifty healthy individuals who came to our hospital for physical examination during the same period were randomly included and defined as the Healthy Control group. PVT1 expression was detected in serum samples from each group using a quantitative reverse transcriptase-polymerase chain reaction , and differences in expression levels were calculated. The ankle-brachial index (ABI) of patients in the LEASO group was measured using a sphygmomanometer, and its correlation with PVT1 was analyzed. Clinical data and laboratory test results (including blood routine, liver and renal function, and blood lipids) were collected for all patients upon admission. Logistic regression analyses were performed to determine the influence of PVT1 and laboratory test results on LEASO. The diagnosis and prediction of LEASO were obtained by combing PVT1 with laboratory test indicators.

Results: It was found that lncRNA PVT1 expression was the highest in the serum of the LEASO with CAD group, followed by the LEASO and control groups ( < 0.05). Within the LEASO group, no significant difference in PVT1 expression was seen between the left and right limbs ( > 0.05), nor between the single and double lower limb groups. Furthermore, the PVT1 expression increased with the Rutherford grades, indicating a negative correlation between PVT1 and ABI. Logistic regression analysis revealed that triglycerides (OR = 2.972, 95% CI [1.159-7.618]), cholesterol (OR = 6.655, 95% CI [1.490-29.723]), C-reactive protein (OR = 1.686, 95% CI [1.218-2.335]), and PVT1 (OR = 2.885, 95% CI [1.350-6.167]) were independent risk factors for LEASO. Finally, strong sensitivity was observed in the receiver operating characteristic curve when combining PVT1 with meaningful laboratory indicators to diagnose and predict LEASO.

Conclusion: lncRNA PVT1 promotes LEASO occurrence and progression and is related to atherosclerosis severity. The expression of PVT1 was negatively correlated with ABI. Logistic regression analysis suggested that blood lipid levels and inflammatory reactions might be related to LEASO occurrence. PVT1 was incorporated into laboratory indicators to predict LEASO. The subject's working curve area was large, and the prediction results were highly sensitive.

References

Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y . High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol. 2008; 28(7):1385-91. DOI: 10.1161/ATVBAHA.107.157164. View

Colombo T, Farina L, Macino G, Paci P . PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int. 2015; 2015:304208. PMC: 4391155. DOI: 10.1155/2015/304208. View

Catapano A, Graham I, De Backer G, Wiklund O, Chapman M, Drexel H . [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]. Kardiol Pol. 2016; 74(11):1234-1318. DOI: 10.5603/KP.2016.0157. View

Abu Dabrh A, Steffen M, Undavalli C, Asi N, Wang Z, Elamin M . The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015; 62(6):1642-51.e3. DOI: 10.1016/j.jvs.2015.07.065. View

Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S:S5-67. DOI: 10.1016/j.jvs.2006.12.037. View

Becker F, Robert-Ebadi H, Ricco J, Setacci C, Cao P, de Donato G . Chapter I: Definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011; 42 Suppl 2:S4-12. DOI: 10.1016/S1078-5884(11)60009-9. View

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

Nickinson A, Coles B, Zaccardi F, Gray L, Payne T, Bown M . Missed Opportunities for Timely Recognition of Chronic Limb Threatening Ischaemia in Patients Undergoing a Major Amputation: A Population Based Cohort Study Using the UK's Clinical Practice Research Datalink. Eur J Vasc Endovasc Surg. 2020; 60(5):703-710. DOI: 10.1016/j.ejvs.2020.05.010. View

Mortensen M, Nordestgaard B . Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020; 396(10263):1644-1652. DOI: 10.1016/S0140-6736(20)32233-9. View

10.

Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier P . ESVM Guideline on peripheral arterial disease. Vasa. 2019; 48(Suppl 102):1-79. DOI: 10.1024/0301-1526/a000834. View

11.

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S . Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2006; 115(4):450-8. DOI: 10.1161/CIRCULATIONAHA.106.637793. View

12.

Quan W, Hu P, Zhao X, Lianhua C, Batu B . Expression level of lncRNA PVT1 in serum of patients with coronary atherosclerosis disease and its clinical significance. Eur Rev Med Pharmacol Sci. 2020; 24(11):6333-6337. DOI: 10.26355/eurrev_202006_21531. View

13.

Kong P, Cui Z, Huang X, Zhang D, Guo R, Han M . Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022; 7(1):131. PMC: 9033871. DOI: 10.1038/s41392-022-00955-7. View

14.

Sun B, Meng M, Wei J, Wang S . Long noncoding RNA PVT1 contributes to vascular endothelial cell proliferation via inhibition of miR-190a-5p in diagnostic biomarker evaluation of chronic heart failure. Exp Ther Med. 2020; 19(5):3348-3354. PMC: 7132232. DOI: 10.3892/etm.2020.8599. View

15.

Zhou T, Ding J, Wang X, Zheng X . Long noncoding RNAs and atherosclerosis. Atherosclerosis. 2016; 248:51-61. DOI: 10.1016/j.atherosclerosis.2016.02.025. View

16.

Emanuele M, Buchanan B, Abraira C . Elevated leg systolic pressures and arterial calcification in diabetic occlusive vascular disease. Diabetes Care. 1981; 4(2):289-92. DOI: 10.2337/diacare.4.2.289. View

17.

Gerhard-Herman M, Gornik H, Barrett C, Barshes N, Corriere M, Drachman D . 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016; 135(12):e686-e725. PMC: 5479414. DOI: 10.1161/CIR.0000000000000470. View

18.

Lu Y, Yuan W, Wang L, Ning M, Han Y, Gu W . Contribution of lncRNA CASC8, CASC11, and PVT1 Genetic Variants to the Susceptibility of Coronary Heart Disease. J Cardiovasc Pharmacol. 2021; 77(6):756-766. DOI: 10.1097/FJC.0000000000001019. View

19.

Wen J, Huang Y, Lu Y, Yuan H . Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population. Hypertens Res. 2019; 42(8):1223-1230. PMC: 8075960. DOI: 10.1038/s41440-019-0251-5. View

20.

Wang Z, Wang X, Hao G, Chen Z, Zhang L, Shao L . A national study of the prevalence and risk factors associated with peripheral arterial disease from China: The China Hypertension Survey, 2012-2015. Int J Cardiol. 2018; 275:165-170. DOI: 10.1016/j.ijcard.2018.10.047. View